Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cathay Biotech's Total Assets for the quarter that ended in Mar. 2026 was ¥24,557 Mil.
Warning Sign:
If a company builds assets at 24.4% a year, faster than its revenue growth rate of 10% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Cathay Biotech's average Total Assets Growth Rate was 9.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 8.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 24.40% per year.
During the past 10 years, Cathay Biotech's highest 3-Year average Total Assets Growth Rate was 53.80%. The lowest was 8.30%. And the median was 27.80%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cathay Biotech's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Cathay Biotech Total Assets Related Terms
Cathay Biotech Total Assets Historical Data
* Premium members only.
The historical data trend for Cathay Biotech's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cathay Biotech's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cathay Biotech (SHSE:688065) has a Total Assets of ¥24,557 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Cathay Biotech and its competitors.
Is Cathay Biotech's Total Assets too high?
Cathay Biotech's current Total Assets is ¥24,557 Mil. Overall, Cathay Biotech has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cathay Biotech's Total Assets compare to DOW?
Cathay Biotech's Total Assets of ¥24,557 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Chemicals company?
A good Total Assets depends on the Chemicals industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Cathay Biotech and its competitors. Cathay Biotech's current Total Assets is ¥24,557 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cathay Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cathay Biotech (SHSE:688065) is currently considered Fairly Valued. The stock's GF Value™ is ¥50.13, compared to a current price of ¥45.80 — trading 8.6% below its estimated fair value. The current Total Assets is ¥24,557 Mil. Cathay Biotech's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Cathay Biotech (SHSE:688065), the current Total Assets is ¥24,557 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cathay Biotech (SHSE:688065) Overvalued in 2026?
Based on GuruFocus' analysis, Cathay Biotech stock appears to be undervalued.
The current stock price of ¥45.80 is trading 8.6% below its estimated GF Value™ of ¥50.13.
GuruFocus considers Cathay Biotech to be Fairly Valued.
Key valuation signals for SHSE:688065:
Total Assets: ¥24,557 Mil
GF Value™: ¥50.13 vs. price of ¥45.80 (8.6% below fair value)
No single metric tells the full story. See the SHSE:688065 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cathay Biotech Inc is engaged in research, development, production, and sales of new bio-based materials. The company owns the TERRYL brand, which focuses on bio-based polyamide fibers for textiles, and ECOPENT, which serves the engineering materials market.
91GF Score
Get the complete analysis for SHSE:688065
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688065 has been successfully added to your 
